TheraRadar
← Back
Data updated: Sep 20, 2026

HAISCO

Pharma
RespiratoryMetabolicImmunology Execution: Fair

HAISCO is a pharmaceutical company focused on Respiratory, Metabolic, Immunology. Key products include CYPSEDO.

2026
Since
1
Drugs
-
Trials
1
New Drugs (2yr)
Modality:
1 Small Molecules

HAISCO at a Glance

  • Growing R&D activity with 46 trials in last 2 years
  • Leading 6 drug targets across portfolio

HAISCO's Key Drugs

HAISCO's core commercial portfolio centers on CYPSEDO, spanning Respiratory and Metabolic — its most strategically important drugs approved in the last 15 years.

CYPSEDO
Approved 2026

HAISCO's Recent FDA Approvals

HAISCO secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.

CYPSEDO NDA
2026-05-29
cipepofol

HAISCO's Therapeutic Areas

HAISCO's approved drugs and pipeline span 5 therapeutic areas, led by Respiratory and Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Respiratory 52%
0 drugs Phase 3: 7 Phase 2: 9
Metabolic 22%
0 drugs Phase 3: 3 Phase 2: 2 Phase 1: 3
Immunology 10%
0 drugs Phase 2: 4 Phase 1: 1
Oncology 9%
0 drugs Phase 1: 8
Infectious Disease 7%
0 drugs Phase 3: 1 Phase 2: 1

HAISCO Pipeline Snapshot

HAISCO has 39 active clinical programs from ClinicalTrials.gov — 11 Phase 3, 16 Phase 2 and 12 Phase 1.

11
Phase 3
16
Phase 2
12
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • CYPSEDO leads revenue
  • • Drug-level revenue analysis

Trial Catalysts

  • • Respiratory pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 13/20 completed
  • • Speed: 7 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges